Study of RO7771950 vs tucatinib for HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, RO7771950, against another drug called tucatinib. Both are given with standard chemotherapy to see which works better for advanced breast cancer that is HER2-positive. People with brain metastases may join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic breast cancer that is HER2-positive, confirmed by a central lab.
- You have measurable disease (stage 1) or non-measurable disease (stage 2) by standard imaging.
- You have had at least one prior anti-HER2 treatment for advanced disease.
- You have had or can have a prior anti-HER2 antibody-drug conjugate (ADC) unless it is not available or safe for you.
- You have not had a tyrosine kinase inhibitor (TKI) for advanced disease, though prior TKI for early-stage cancer is okay if completed over a year ago.
- Your organs and bone marrow work well, you are up and about (ECOG 0 or 1), and your heart function is normal (LVEF at least 50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
This Phase 2 trial tests a combination of tucatinib and capecitabine (taken by mouth) plus trastuzumab delivered into the spinal fluid, to treat breast cancer that has spread to the leptomeninges (lining around the brain/spinal cord). It may help reduce cancer activity in the spinal fluid and improve symptoms.
This trial tests a combination of two targeted drugs (tucatinib and trastuzumab) for people with a specific gene change (HER3 mutation) in advanced breast cancer that has spread or cannot be removed by surgery. It may be an option if you have already had at least two previous treatments.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.